Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Achneck Hardean — Aligos Therapeutics, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / Achneck Hardean

Achneck Hardean

Chief Medical Officer at Aligos Therapeutics, Inc. · on record since Sep 26, 2024

Insider trading activity of Achneck Hardean

Transactions on record: 1; since Oct 10, 2024

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Oct 10, 2024

Figures computed from official regulatory filings — methodology.

Companies where Achneck Hardean has traded

Aligos Therapeutics, Inc.1 tx · Oct 10, 2024

Track record of Achneck Hardean

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Achneck Hardean

Co-insiders of Achneck Hardean

Aneja NikhilAligos Therapeutics, Inc.
Beigelman LeonidAligos Therapeutics, Inc.
BLATT LAWRENCEAligos Therapeutics, Inc.
Calhoun Lesley AnnAligos Therapeutics, Inc.
Chavez MargaritaAligos Therapeutics, Inc.
Glaub Kathleen SeredaAligos Therapeutics, Inc.
Hirth PeterAligos Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Martell Bridget AAligos Therapeutics, Inc.

McClure Matthew W.Aligos Therapeutics, Inc.

Moldt PeterAligos Therapeutics, Inc.

Nielsen JackAligos Therapeutics, Inc.

Novo A/SAligos Therapeutics, Inc.

Nuechterlein CaroleAligos Therapeutics, Inc.

Preston HeatherAligos Therapeutics, Inc.

Quan Lucinda Y.Aligos Therapeutics, Inc.

ROCHE FINANCE LTDAligos Therapeutics, Inc.

ROCHE HOLDING LTDAligos Therapeutics, Inc.

Scopa James PaulAligos Therapeutics, Inc.

Symons Julian A.Aligos Therapeutics, Inc.

Versant Vantage I, L.P.Aligos Therapeutics, Inc.

Versant Venture Capital VI, L.P.Aligos Therapeutics, Inc.

Vivo Capital Fund VIII, L.P.Aligos Therapeutics, Inc.

Vivo Capital Surplus Fund VIII, L.P.Aligos Therapeutics, Inc.

Vivo Capital VIII, LLCAligos Therapeutics, Inc.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Aligos Therapeutics, Inc.

Woiwode ThomasAligos Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Aligos Therapeutics, Inc.	Oct 10, 2024	AwardD	75,000	0.00 USD	$0	SEC